Abstract
Primary and adaptive resistance to immune checkpoint therapies (ICT) represent a considerable obstacle to achieving enhanced overall survival. Innate immune activators have been actively pursued for their antitumor potential. Herein we report that a syngeneic 4T1 mammary carcinoma murine model for established highly-refractory triple negative breast cancer showed enhanced survival when treated intra-tumorally with either the TLR5 agonist flagellin or CBLB502, a flagellin derivative, in combination with antibodies targeting CTLA-4 and PD-1. Long-term survivor mice showed immunologic memory upon tumor re-challenge and a distinctive immune activating cytokine profile that engaged both innate and adaptive immunity. Low serum levels of G-CSF and CXCL5 (as well as high IL-15) were candidate predictive biomarkers correlating with enhanced survival. CBLB502-induced enhancement of ICT was also observed in poorly immunogenic B16-F10 melanoma tumors. Combination immune checkpoint therapy plus TLR5 agonists may offer a new therapeutic strategy to treat ICT-refractory solid tumors.
Original language | English (US) |
---|---|
Article number | 31 |
Journal | Communications Biology |
Volume | 6 |
Issue number | 1 |
DOIs | |
State | Published - Dec 2023 |
ASJC Scopus subject areas
- Medicine (miscellaneous)
- General Biochemistry, Genetics and Molecular Biology
- General Agricultural and Biological Sciences
MD Anderson CCSG core facilities
- Flow Cytometry and Cellular Imaging Facility